HOUSTON--(BUSINESS WIRE)--Saranas, a medical device company with a new technology for real-time detection and monitoring of internal bleeding during endovascular procedures, has been invited to present at the 29th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation (CRF), Oct. 31, 2017, in Denver, CO. Saranas was chosen to participate in the conference’s Shark Tank Competition. The company’s lead product, the Early Bird™ Bleed Monitoring System, is undergoing final product testing. FDA submission is expected later this year.
President and CEO Zaffer Syed said, “We are very excited to be chosen to present at this prestigious conference, especially from a highly competitive field. We believe the Early Bird system is potentially an important medical advancement for patients who can be affected by serious bleeding complications during endovascular procedures. Presenting at TCT gives us the opportunity to discuss exactly how the Early Bird can do that.”
The Early Bird includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as transcatheter aortic valve replacement, large bore hemodynamic support device placement, or other complex cardiac interventions, where the femoral artery or vein is used to gain vascular access to the heart. The technology was invented at the Texas Heart Institute.
About Saranas
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, visit www.saranas.com.
